目的：观察重组人血管内皮抑素（恩度）联合吉西他滨治疗晚期肝细胞癌的远期疗效。方法将57例Ⅳ期肝细胞癌患者随机分为2组，恩度组29例予恩度联合吉西他滨方案治疗，对照组28例予吉西他滨方案治疗，2组患者均至少接受2周期化疗，比较分析2组患者的1 a、2 a、3 a 生存率及中位生存期。结果恩度组、对照组的中位生存期分别为8.3个月、6.1个月，1 a 生存率分别为41.4%、25.0%，2 a 生存率分别为31.0%、10.7%，3 a 生存率分别为13.8%、0.0%，虽然恩度组具有一定优势，但差异均无统计学意义（P 均﹥0.05）。结论恩度联合吉西他滨治疗晚期肝细胞癌远期疗效较好，可能具有改善患者生存的作用，值得进一步研究。%Objective To investigate the long-term efficacy of recombinant human vascular endostatin( en-dostar)combined with gemcitabine in the treatment of advanced hepatocellular carcinoma. Methods Fifty-seven patients with stage Ⅳ advanced hepatocellular carcinoma were randomly divided into two groups. The 29 patients in the treatment group received endostar plus gemcitabine regimen,and the other 28 patients in the control group were given with gemcitabine chemotherapy only. All the patients received at least 2 cycles of chemotherapy. The 1-year, the 2-year,the 3-year overall survival rates and median overall survival time were analyzed retrospectively. Results The 1-year overall survival rate was 41. 4% % in the treatment group,and was 25. 0% in the control group(P ﹥0. 05). The 2-year overall survival rate was 31. 0% in the treatment group,and was 10. 7% in the control group (P ﹥ 0. 05). The 3-year overall survival rate was 13. 8% in the treatment group,and was 0. 0% in the control group (P ﹥ 0. 05). The median overall survival time was 8. 3 months in the treatment group,and was 6. 1 months in the control group(P ﹥ 0. 05). Conclusion Endostar combined with gemcitabine is effect in the treatment of advanced hepatocellular carcinoma,the survival time may be prolonged by endostar combined with gemcitabine.
展开▼
